Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrrolitinib plus albumin-bound paclitaxel as adjuvant therapy for HER2-positive early breast cancer
ChiCTR2400082388Phase 4Not yet recruiting
- Sponsor
- Weihai Municipal Hospital
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pyrotinib in breast cancer (2 cohorts), sponsored by Weihai Municipal Hospital. Primary endpoint: Invasive disease-free survival (iDFS). Planned start Mar 2024; status: not yet recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400082388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082388.